Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
941 to 960 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer. | Transl Oncol | 2022 | 35917645 | PubTator, text mining | PubMed |
| Analysis of Competitive Endogenous Mechanism and Survival Prognosis of Serum Exosomes in Ovarian Cancer Patients Based on Sequencing Technology and Bioinformatics. | Front Genet | 2022 | 35910206 | PubTator, text mining | PubMed |
| A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer. | J Oncol | 2022 | 35909902 | PubTator, text mining | PubMed |
| [Oncogénétique dans les cancers de l'ovaire]. | Rev Prat | 2022 | 35899665 | PubTator, text mining | PubMed |
| Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review. | Front Pharmacol | 2022 | 35899114 | PubTator, text mining | PubMed |
| Opinion: PARP inhibitors in cancer-what do we still need to know? | Open Biol | 2022 | 35892198 | PubTator, text mining | PubMed |
| Comprehensive Genomic Profiling in the Management of Ovarian Cancer-National Results from Croatia. | J Pers Med | 2022 | 35887672 | PubTator, text mining | PubMed |
| Hereditary Diffuse Gastric Cancer: Molecular Genetics, Biological Mechanisms and Current Therapeutic Approaches. | Int J Mol Sci | 2022 | 35887173 | PubTator, text mining | PubMed |
| Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. | Int J Environ Res Public Health | 2022 | 35886427 | PubTator, text mining | PubMed |
| Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy. | Genes (Basel) | 2022 | 35886069 | PubTator, text mining | PubMed |
| Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry. | Cancers (Basel) | 2022 | 35884425 | PubTator, text mining | PubMed |
| DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers. | J Exp Clin Cancer Res | 2022 | 35883104 | PubTator, text mining | PubMed |
| Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. | Clin Cancer Res | 2022 | 35881546 | PubTator, text mining | PubMed |
| Beyond controlling cell size: functional analyses of S6K in tumorigenesis. | Cell Death Dis | 2022 | 35879299 | PubTator, text mining | PubMed |
| Emerging Biomarker-Guided Therapies in Prostate Cancer. | Curr Oncol | 2022 | 35877260 | PubTator, text mining | PubMed |
| Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention. | Curr Oncol | 2022 | 35877228 | PubTator, text mining | PubMed |
| Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development. | Front Pharmacol | 2022 | 35873570 | PubTator, text mining | PubMed |
| The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer. | Clin Genitourin Cancer | 2022 | 35871039 | PubTator, text mining | PubMed |
| Influence of germline test results on surgical decision making in women with invasive breast cancer. | Cancer Genet | 2022 | 35868102 | PubTator, text mining | PubMed |
| Case Report: A Rare Case of Hepatoid Adenocarcinoma in Stomach and Duodenum Simultaneously. | Cancer Manag Res | 2022 | 35859712 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=48